HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 45 (1) , 119-126
- https://doi.org/10.1053/j.ajkd.2004.09.025
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Editorials: Are HMG‐CoA Reductase Inhibitors Underutilized in Dialysis Patients?Seminars in Dialysis, 2003
- Study of Heart and Renal Protection (SHARP)Kidney International, 2003
- Why do we need a statin trial in hemodialysis patients?Kidney International, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPDKidney International, 2002
- HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patientsKidney International, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- The Dialysis Outcomes and Practice Patterns Study (DOPPS): How Can We Improve the Care of Hemodialysis Patients?Seminars in Dialysis, 2001
- The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis studyKidney International, 2000
- Survival Analysis Techniques for Censored and Truncated DataTechnometrics, 1998